News tagged with her2 receptor
Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Jan 16, 2012 |
5 / 5 (2) |
0
|
Researchers use light to measure cancer cells' response to treatment
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon ...
Dec 20, 2011 |
5 / 5 (1) |
0
New study shows biopsy of recurrent breast cancer can alter treatment
A second, larger clinical research study led by breast cancer specialists at Princess Margaret Hospital (PMH) has again proven that comparing a new biopsy of progressing or recurring cancer with that of the original cancer ...
Nov 28, 2011 |
5 / 5 (1) |
0
|
Scientists identify overactive genes in aggressive breast cancers
Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that ...
Jun 01, 2011 |
not rated yet |
0
|
Fox Chase clinical trial tests first of its kind antibody
Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type ...
Jun 04, 2010 |
not rated yet |
0
Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies
An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule.
May 06, 2010 |
not rated yet |
0
Which is promising as therapeutic targets in patients with biliary tract cancer? EGFR or HER2?
A research team from Germany analyzed the pathogenetic role and potential clinical usefulness of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) in patients with advanced ...
Oct 16, 2009 |
not rated yet |
0
Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast ...
May 28, 2009 |
not rated yet |
0
African-American women with advanced breast cancer often forego vital treatment
A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies. Published in the July 1, 2009 issue of Cancer, a peer ...
May 22, 2009 |
not rated yet |
1
New radiation-free targeted therapy detects and eliminates breast cancer tumors in mice
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, ...
Mar 30, 2009 |
5 / 5 (1) |
0
